TrianglePUBLICATIONS · 36460017
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAF(V600) mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- Lancet Oncol
- Publication date
- 2023 Jan
- First author
- Ascierto PA
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Ascierto PA
- type
- Author
- name
- Stroyakovskiy D
- type
- Author
- name
- Gogas H
- type
- Author
- name
- Robert C
- type
- Author
- name
- Lewis K
- type
- Author
- name
- Protsenko S
- type
- Author
- name
- Pereira RP
- type
- Author
- name
- Eigentler T
- type
- Author
- name
- Rutkowski P
- type
- Author
- name
- Demidov L
- type
- Author
- name
- Zhukova N
- type
- Author
- name
- Schachter J
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Ascierto PA
- type
- Author
- name
- Stroyakovskiy D
- type
- Author
- name
- Gogas H
- type
- Author
- name
- Robert C
- type
- Author
- name
- Lewis K
- type
- Author
- name
- Protsenko S
- type
- Author
- name
- Pereira RP
- type
- Author
- name
- Eigentler T
- type
- Author
- name
- Rutkowski P
- type
- Author
- name
- Demidov L
- type
- Author
- name
- Zhukova N
- type
- Author
- name
- Schachter J
- type
- Author
- bibliography ids
- nci-bib-ee029ff85a21a3567cb39c6a
- book metadata
- content sha256
- 579f3f3cba9666c30a7fb4ce1da73477e5601c105b72a2dccade5aed4662663a
- document type
- citation
- dois
- 10.1016/S1470-2045(22)00687-8
- electronic publication date
- display
- 2022 Nov 29
- precision
- day
- year
- 2022
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:36460017
- immutable id
- pubmed:36460017@579f3f3cba9666c30a7fb4ce1da73477e5601c105b72a2dccade5aed4662663a
- journal
- abbreviation
- Lancet Oncol
- issn electronic
- 1474-5488
- issn print
- 1470-2045
- issue
- 1
- name
- The Lancet. Oncology
- nlm unique id
- 100957246
- pages
- 33-44
- volume
- 24
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 36460017
- provenance
- batch id
- d370e99271168e8a8a13
- provider
- NCBI PubMed ESummary
- record sha256
- 01d889698cf65af66b8f2a51ce7adbda15e3cc3cb500627939ee3e0c8e864a60
- response sha256
- f65ace3ceb1efa86f3fbab8e01ce265243e7c6b7f13c5f71c357c1f219ad79c4
- retrieved at
- 2026-09-09T23:48:13.005737+00:00
- publication date
- display
- 2023 Jan
- precision
- month
- year
- 2023
- publication types
- Randomized Controlled Trial
- Multicenter Study
- Clinical Trial, Phase III
- Journal Article
- Research Support, Non-U.S. Gov't
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAF(V600) mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study.
Preserved source evidence · Independent clinical review pending · Not medical advice